Analysis Reports - TradeFomo

Deep-dive AI research reports on individual stocks, powered by our proprietary signals. Every report carries a direction (Bullish or Bearish) and a conviction level(Strong or Speculative). We track stock performance since each report's publication date — because we believe great analysis should be held accountable.

All AAOI ACAD ADMA AGIO ALMS ALMU ALTS APGE AUPH AVAV BCRX CAI CAKE CEG CELC CEP CGON CIEN CNC COGT CRCL CTRI GCT GOOG GPCR HALO HIMS HOOD HWM IREN IVVD KALA KALV LENZ LEVI LITE LRMR LULU LUNR MDGL MESO MOH MTCH MU MVST NBIS NKE NRIX NVAX OKUR OLMA ONC OSCR PHAT PLRX PYG RBLX RDDT RIGL RKLB SGHC SPRY SRPT TARS TBPH TH TRVI TSHA UNH VEON VOR WVE XFOR ZLAB

$Trevi Therapeutics (TRVI) is a clinical-stage biopharmaceutical company focused on developing its sole asset, Haduvio (oral nalbuphine ER), as a first-in-class treatment for chronic cough in Idiopathic Pulmonary Fibrosis (IPF) and Refractory Chronic Cough (RCC)—conditions with no approved therapies in the U.S. The drug demonstrated strong efficacy in Phase 2 trials (CORAL for IPF and RIVER for RCC), showing significant cough reduction and a manageable safety profile. With a cash runway extending into 2029 following a recent $115 million financing, the company is well-positioned to advance into Phase 3 trials starting in H1 2026. Despite promising clinical and financial de-risking, investment carries significant risks due to its single-asset focus, potential Phase 3 failure, and commercialization challenges. A "Buy" recommendation is advised for high-risk, long-term investors, given the asymmetric upside potential.$

An Investment Analysis of Trevi Therapeutics, Inc. (TRVI)

2025-09-17Change from report: +65.3%1M: +29.8%3M: +51.8%

Trevi Therapeutics (TRVI) is a clinical-stage biopharmaceutical company focused on developing its sole asset, Haduvio (oral nalbuphine ER), as a first-in-class treatment for chronic cough in Idiopathic Pulmonary Fibrosis (IPF) and Refractory Chronic Cough (RCC)—conditions with no approved therapies in the U.S. The drug demonstrated strong efficacy in Phase 2 trials (CORAL for IPF and RIVER for RCC), showing significant cough reduction and a manageable safety profile. With a cash runway extending into 2029 following a recent $115 million financing, the company is well-positioned to advance into Phase 3 trials starting in H1 2026. Despite promising clinical and financial de-risking, investment carries significant risks due to its single-asset focus, potential Phase 3 failure, and commercialization challenges. A "Buy" recommendation is advised for high-risk, long-term investors, given the asymmetric upside potential.